COMPANY RESEARCHClinical CRO services include operations, regulatory affairs, pharmacovigilance, data management and statistics, SMO, and laboratories. Frontage is consolidated.
Profile review: 2026-11-06 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
| Period | Currency / basis | Revenue | Net profit | Operating cash flow | Report |
|---|---|---|---|---|---|
| FY2025 2025-12-31 | CNY PRC Accounting Standards / consolidated | 6,832,800,615.35 | 887,890,076.31 Net income attributable to shareholders of the listed company | 1,118,084,770.54 | Original ↗ |
| 2026Q3 (YTD) 2026-09-30 | CNY PRC Accounting Standards / consolidated | 5,791,528,067.34 | -272,048,633.37 Net income attributable to shareholders of the listed company | 771,311,923.45 | Original ↗ |
Disease tags match recorded text mentions and require program-level verification.
Clinical CRO services include operations, regulatory affairs, pharmacovigilance, data management and statistics, SMO, and laboratories. Frontage is consolidated.
Listed as SZSE 300347 / HKEX 03347; original 2025 annual and 2026Q3 (YTD) reports reviewed.
China-origin global clinical CRO with a disclosed Chinese investigator network and cross-regional development services. Historical offering documents reference IITs; confirm current indication-specific IIT staffing and scope.
International delivery scope: China-based / China-origin platform
IIT evidence: Historical IIT disclosure; current scope to confirm
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| End-to-end clinical trial services | Not applicable (services/platform) · Drug research and manufacturing services for clients | Services / platform | Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Tigermed reported consolidated revenue of RMB5.792 billion, up 15.23%, and an attributable net loss of RMB272.0 million for the nine months ended September 30, 2026. Profit excluding nonrecurring items reached RMB450.1 million, up 38.08%; investment losses weighed on reported earnings. The quarterly filing is unaudited and covers the year-to-date period.
CSPC announced initiation of the first Chinese center for SYS6055-003, a Phase 1/2 trial in relapsed or refractory B-cell non-Hodgkin lymphoma. SYS6055 uses lentiviral vectors to generate CD19-targeting CAR-T cells in vivo. The company said recruitment and screening are underway following October clinical-trial authorization. Center initiation does not establish patient dosing, efficacy, or marketing approval.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
The China National Center for Biotechnology Development published its fifteenth batch of biomedical clinical research filings on November 4. Seven projects completed filing between October 27 and November 4. The notice emphasizes institutional responsibility, internal quality management, training, data traceability, and participant protection. Filing concerns the research pathway; it is not evidence of therapeutic efficacy or product marketing authorization.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.